Pharmaceutical Medicine

, Volume 23, Issue 3, pp 165–175 | Cite as

Forum

Update
  • 13 Downloads

References

Reference

  1. Food and Drug Administration. Guidance for industry: presenting risk information in prescription drug and medical device promotion. May 2009 [online]. Available from URL: http://www.fda.gov [Accessed 2009 Jul 20]

Reference

  1. O’Dowd A. Safety watchdog warns of high dosage errors among children and young people. BMJ 2009; 338: 2500CrossRefGoogle Scholar

References

  1. 1.
    Federal Trade Commission. FTC issues interim report on authorized generic drugs. Media Release: 24 Jun 2009 [online]. Available from URL: http://www.ftc.gov [Accessed 2009 Jul 1]Google Scholar
  2. 2.
    Federal Trade Commission. FTC Chairman Leibowitz: eliminating pay-for-delay pharmaceutical settlements would save consumers $3.5 billion annually. Media Release: 23 Jun 2009 [online]. Available from URL: http://www.ftc.gov [Accessed 2009 Jul 1]Google Scholar

References

  1. 1.
    Adams AS, Zhang F, LeCates RF, et al. Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees. Arch Intern Med 2009; 169 (8): 750–6PubMedCrossRefGoogle Scholar
  2. 2.
    Solomon MD, Goldman DP, Joyce GF, et al. Cost sharing and the initiation of drug therapy for the chronically ill. Arch Intern Med 2009; 169 (8): 740–8PubMedCrossRefGoogle Scholar
  3. 3.
    Goff Jr DC, Greenland P. The change we need in health care. Arch Intern Med 2009; 169 (8): 737–9PubMedCrossRefGoogle Scholar
  4. 4.
    Majumdar SR. Invited commentary. Arch InternMed 2009; 169 (8): 748–9CrossRefGoogle Scholar

References

  1. 1.
    Institute of Medicine. IOM report recommends 100 initial priorities for research to determine which health care approaches work best. Media Release: 30 Jun 2009 [online]. Available from URL: http://www.iom.edu [Accessed 2009 Jul 1]Google Scholar
  2. 2.
    Taylor L. US effectiveness studies must focus on groups missed by medical research. 30 Jun 2009 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2009 Jul 1]Google Scholar

Reference

  1. National Minority Quality Forum. Report reveals disparities in pharmaceutical treatment for minority patients. Media Release: 12 May 2009 [online]. Available from URL: http://www.nmqf.org [Accessed 2009 Jun 11]Google Scholar

Reference

  1. Lokker N, Sanders L, Perrin EM, et al. Parental misinterpretations of over-the-counter pediatric cough and cold medication labels. Pediatrics 2009; 123 (6): 1464–71PubMedCrossRefGoogle Scholar

Reference

  1. Zarocostas J. Huge inequalities in access to drugs partly because of intellectual property rights, says UN expert. BMJ 2009; 339: 2877CrossRefGoogle Scholar

Reference

  1. The Global Alliance for Chronic Diseases. Six of the world’s foremost health research agencies form alliance to curb humanity’s most fatal disease. Media Release: 15 Jun 2009 [online]. Available from URL: http://www.gafcd.org [Accessed 2009 Jun 22]Google Scholar

Reference

  1. BBC News. Obama welcomes healthcare pledge. 11 May 2009 [online]. Available from URL: http://www.news.bbc.co.uk [Accessed 2009 May 14]Google Scholar

References

  1. 1.
    Garber AM, Tunis SR. Does comparative-effectiveness research threaten personalized medicine? N Engl J Med 2009; 360 (19): 1925–7PubMedCrossRefGoogle Scholar
  2. 2.
    Avorn J. Debate about funding comparative-effectiveness research. N Engl J Med 2009; 360 (19): 1927–9PubMedCrossRefGoogle Scholar
  3. 3.
    Naik AD, Petersen LA. The neglected purpose of comparativeeffectiveness research. N Engl J Med 2009; 360 (19): 1929–31PubMedCrossRefGoogle Scholar

Reference

  1. Taylor L. Australian pharma forced to fund govt drugs panel. 13 May 2009 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2009 May 14]Google Scholar

Reference

  1. Wilking NE, Jönsson B. The access to oncology drugs in France, Germany, Italy, Spain, and the United Kingdom: a comparison based on data from 1998 to 2007 [abstract no. 6525]. 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–31; Orlando (FL). Available from URL: http://www.abstract.asco.org [Accessed 2009 Jul 20]Google Scholar

Reference

  1. National Institute for Health and Clinical Excellence. NICE short clinical guideline increases treatment options for patients with type 2 diabetes. Media Release: 27 May 2009 [online]. Available from URL: http://www.nice.org.uk [Accessed 2009 Jul 20]Google Scholar

Reference

  1. Visvanathan K, Chlebowski RT, Hurley P, et al. American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 2009; 27 (19): 3235–58PubMedCrossRefGoogle Scholar

Reference

  1. American Academy of Dermatology. American Academy of Dermatology issues new guidelines for the management of psoriasis with systemic medications. Media Release: 4 Jun 2009 [online]. Available from URL: http://www.aad.org [Accessed 2009 Jun 15]Google Scholar

Reference

  1. Kmietowicz Z. Pilot projects for personal health budgets in England are announced. BMJ 2009; 338: 1996CrossRefGoogle Scholar

References

  1. 1.
    Pindolia VK, Stebelsky L, Romain TM, et al. Mitigation of medication mishaps via medication therapy management. Ann Pharmacother 2009; 43 (4): 611–20PubMedCrossRefGoogle Scholar
  2. 2.
    Welch EK, Delate T, Chester EA, et al. Assessment of the impact of medication therapy management delivered to home-based Medicare beneficiaries. Ann Pharmacother 2009; 43 (4): 603–10PubMedCrossRefGoogle Scholar

Reference

  1. Pfizer. Pfizer launches free medicines program for newly unemployed Americans. Media Release: 14 May 2009 [online]. Available from URL: http://www.pfizer.com [Accessed 2009 Jun 15]Google Scholar

Reference

  1. Taylor L. Obama plans $75 billion cuts in drug spending. 14 Jun 2009 [online]. Available from URL: http://www.pharmatimes.com [Accessed 2009 Jun 18]Google Scholar

References

  1. 1.
    Iglehart JK. Finding money for health care reform — rooting out waste, fraud, and abuse. N Engl J Med 2009; 361: 229PubMedCrossRefGoogle Scholar
  2. 2.
    Gruber J. A win-win approach to financing health care reform. N Engl J Med 2009; 361: 4PubMedCrossRefGoogle Scholar

Reference

  1. Kalorama Information. Cancer biotherapy market could reach $60 billion in ten years. Media Release: 12 May 2009 [online]. Available from URL: http://www.kaloramainvormation.com [Accessed 2009 Jul 20]Google Scholar

Reference

  1. Wright C. Scottish body assesses drugs at a fraction of cost of NICE, its chairman says. BMJ 2009; 338: 2560CrossRefGoogle Scholar

Reference

  1. National Institute for Clinical Excellence. Citizens Council report on departing from the threshold. 29 May 2009 [online]. Available from URL: http://www.nice.org.uk [Accessed 2009 Jul 20]Google Scholar

Reference

  1. Prescription Solutions. Many Americans still have limited knowledge of generic drugs, new UnitedHealth Group study finds. Media Release: 22 Jun 2009 [online]. Available from URL: http://www.prescriptionsolutions.com [Accessed 2009 Jul 20]Google Scholar

Reference

  1. Moszynski P. Health care in poor countries must be defended against privatisation, Oxfam says. BMJ 2009; 339: 2737CrossRefGoogle Scholar

Reference

  1. World Health Organization Maximizing Positive Synergies Collaborative Group. An assessment of interactions between global health initiatives and country health systems. Lancet 2009; 373 (9681): 2137–69CrossRefGoogle Scholar

Reference

  1. Decision Resources Inc. European prices of 170 best-selling drugs averaged 40 percent less than U.S. prices in 2008. Media Release: 7 Jul 2009 [online]. Available from URL: http://www.decisionresources.com [Accessed 2009 Jul 17]Google Scholar

Reference

  1. Cheraghali AM, Idries AM. Availability, affordability, and prescribing pattern of medicines in Sudan. Pharm World Sci 2009; 31 (2): 209–15PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Personalised recommendations